-
1 week ago | 
healio.com | Raj Chovatiya |Erin Michael
In this video,Raj Chovatiya, MD, PhD, discusses the latest findings on the use of topical roflumilast in patients with psoriasis presented at the 2025 Academy of Dermatology Annual Meeting.
-
1 month ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“I introduce the idea of topical non-steroidals very early. I think that when you really try to emphasize the fact that topical steroids were made for certain things and not made for others, it makes that discussion a little easier when you try to introduce some of our newer options,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
1 month ago | 
healio.com | Raj Chovatiya |Erin Michael
Healio spoke with Raj Chovatiya, MD, PhD, about results from the phase 3 ICONIC-LEAD trial presented at the 2025 Academy of Dermatology Annual Meeting. The study assessed the use of the interleukin-23 inhibitor icotrokinra (Protagonist Therapeutics, Johnson & Johnson) in adult and adolescent patients with moderate-to-severe plaque psoriasis.
-
1 month ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“JAK inhibitors have really given us additional options for therapy in the last few years that we didn't have for our patients, particularly oral therapeutics, something that's been lacking in this disease space,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
1 month ago | 
healio.com | Raj Chovatiya |Erin Michael
In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American Academy of Dermatology Annual Meeting. The study assessed the use of ESK-001 (Alumis), an oral tyrosine kinase 2 inhibitor, among patients with moderate-to-severe plaque psoriasis.
-
1 month ago | 
healio.com | Raj Chovatiya |Erin Michael |Carol L. DiBerardino
In this video, Raj Chovatiya, MD, PhD, discusses updates on oral therapies in psoriasis from the American Academy of Dermatology Annual Meeting. “We saw updates largely in the oral therapeutic realm, even more so than the biologic therapeutic realm,” Chovatiya, who is a clinical associate professor for Chicago Medical School at Rosalind Franklin University and assistant clinical professor at George Washington University School of Health Sciences, said.
-
1 month ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“RAD is one-stop shop for everything happening in education, clinical practice, and research for atopic dermatitis,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
1 month ago | 
ajmc.com | Cameron Santoro |Raj Chovatiya
Raj Chovatiya, MD, PhD, MSCI, clinical associate professor of medicine at Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology/Immunology Research, highlights several aspects that distinguish lebrikizumab (Ebglyss; Eli Lilly) from other biologics targeting the IL-4/IL-13 pathway, based on recent data from various studies.
-
1 month ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“Chronic hand eczema can be a tricky diagnosis and a tricky thing to treat, in part because we don't always agree on what the diagnosis is. As long as you've had multiple bouts of eczema on your hands in one year, or a particular symptom of patterns that have been going on for at least 3 months, you really fit the bill for chronic hand eczema,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
1 month ago | 
ajmc.com | Cameron Santoro |Raj Chovatiya
Raj Chovatiya, MD, PhD, MSCI, clinical associate professor of medicine at Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology/Immunology Research, emphasizes promising atopic dermatitis research aiming to identify patient subgroups for targeted treatments using biomarkers and clinical traits.
